<?xml version='1.0' encoding='utf-8'?>
<document id="18950380"><sentence text="Pharmacokinetic interaction between tandospirone and fluvoxamine in the rat contextual conditioned fear stress model and its functional consequence: Involvement of cytochrome P450 3A4."><entity charOffset="36-48" id="DDI-PubMed.18950380.s1.e0" text="tandospirone" /><entity charOffset="53-64" id="DDI-PubMed.18950380.s1.e1" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.18950380.s1.e0" e2="DDI-PubMed.18950380.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18950380.s1.e0" e2="DDI-PubMed.18950380.s1.e1" /></sentence><sentence text="In a previous study it was demonstrated that the anxiolytic action of tandospirone, a 5-hydroxytryptamine (5-HT)(1A) receptor agonist, is facilitated by cytochrome P450 (CYP) 3A4 inhibitors, such as ketoconazole and cimetidine"><entity charOffset="70-82" id="DDI-PubMed.18950380.s2.e0" text="tandospirone" /><entity charOffset="86-105" id="DDI-PubMed.18950380.s2.e1" text="5-hydroxytryptamine" /><entity charOffset="199-211" id="DDI-PubMed.18950380.s2.e2" text="ketoconazole" /><entity charOffset="216-226" id="DDI-PubMed.18950380.s2.e3" text="cimetidine" /><pair ddi="false" e1="DDI-PubMed.18950380.s2.e0" e2="DDI-PubMed.18950380.s2.e0" /><pair ddi="false" e1="DDI-PubMed.18950380.s2.e0" e2="DDI-PubMed.18950380.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18950380.s2.e0" e2="DDI-PubMed.18950380.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18950380.s2.e0" e2="DDI-PubMed.18950380.s2.e3" /><pair ddi="false" e1="DDI-PubMed.18950380.s2.e1" e2="DDI-PubMed.18950380.s2.e1" /><pair ddi="false" e1="DDI-PubMed.18950380.s2.e1" e2="DDI-PubMed.18950380.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18950380.s2.e1" e2="DDI-PubMed.18950380.s2.e3" /><pair ddi="false" e1="DDI-PubMed.18950380.s2.e2" e2="DDI-PubMed.18950380.s2.e2" /><pair ddi="false" e1="DDI-PubMed.18950380.s2.e2" e2="DDI-PubMed.18950380.s2.e3" /></sentence><sentence text=" It is also known that fluvoxamine, a selective serotonin re-uptake inhibitor (SSRI), inhibits CYP3A4"><entity charOffset="23-34" id="DDI-PubMed.18950380.s3.e0" text="fluvoxamine" /><entity charOffset="48-57" id="DDI-PubMed.18950380.s3.e1" text="serotonin" /><pair ddi="false" e1="DDI-PubMed.18950380.s3.e0" e2="DDI-PubMed.18950380.s3.e0" /><pair ddi="false" e1="DDI-PubMed.18950380.s3.e0" e2="DDI-PubMed.18950380.s3.e1" /></sentence><sentence text=" The purpose of the present study was to clarify the pharmacokinetic interaction between tandospirone and fluvoxamine and to evaluate their combined effect in the rat anxiety model"><entity charOffset="89-101" id="DDI-PubMed.18950380.s4.e0" text="tandospirone" /><entity charOffset="106-117" id="DDI-PubMed.18950380.s4.e1" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.18950380.s4.e0" e2="DDI-PubMed.18950380.s4.e0" /><pair ddi="false" e1="DDI-PubMed.18950380.s4.e0" e2="DDI-PubMed.18950380.s4.e1" /></sentence><sentence text="" /><sentence text="The anxiolytic action of co-administration of tandospirone and fluvoxamine was examined using the rat contextual conditioned fear stress model"><entity charOffset="46-58" id="DDI-PubMed.18950380.s6.e0" text="tandospirone" /><entity charOffset="63-74" id="DDI-PubMed.18950380.s6.e1" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.18950380.s6.e0" e2="DDI-PubMed.18950380.s6.e0" /><pair ddi="false" e1="DDI-PubMed.18950380.s6.e0" e2="DDI-PubMed.18950380.s6.e1" /></sentence><sentence text=" After testing the conditioned fear, plasma concentrations of tandospirone and its major metabolite 1-(2-pyrimidyl) piperazine were determined"><entity charOffset="62-74" id="DDI-PubMed.18950380.s7.e0" text="tandospirone" /><entity charOffset="100-126" id="DDI-PubMed.18950380.s7.e1" text="1-(2-pyrimidyl) piperazine" /><pair ddi="false" e1="DDI-PubMed.18950380.s7.e0" e2="DDI-PubMed.18950380.s7.e0" /><pair ddi="false" e1="DDI-PubMed.18950380.s7.e0" e2="DDI-PubMed.18950380.s7.e1" /></sentence><sentence text="" /><sentence text="One day after fear conditioning, both tandospirone (60 mg/kg, p"><entity charOffset="38-50" id="DDI-PubMed.18950380.s9.e0" text="tandospirone" /></sentence><sentence text="o" /><sentence text=") and fluvoxamine (60 mg/kg, p"><entity charOffset="6-17" id="DDI-PubMed.18950380.s11.e0" text="fluvoxamine" /></sentence><sentence text="o" /><sentence text=") significantly inhibited conditioned freezing and their combination effect was additive" /><sentence text=" In addition, plasma concentration of tandospirone was increased by fluvoxamine"><entity charOffset="38-50" id="DDI-PubMed.18950380.s14.e0" text="tandospirone" /><entity charOffset="68-79" id="DDI-PubMed.18950380.s14.e1" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.18950380.s14.e0" e2="DDI-PubMed.18950380.s14.e0" /><pair ddi="false" e1="DDI-PubMed.18950380.s14.e0" e2="DDI-PubMed.18950380.s14.e1" /></sentence><sentence text="" /><sentence text="There is a CYP3A4-related drug-drug interaction between tandospirone and fluvoxamine"><entity charOffset="56-68" id="DDI-PubMed.18950380.s16.e0" text="tandospirone" /><entity charOffset="73-84" id="DDI-PubMed.18950380.s16.e1" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.18950380.s16.e0" e2="DDI-PubMed.18950380.s16.e0" /><pair ddi="false" e1="DDI-PubMed.18950380.s16.e0" e2="DDI-PubMed.18950380.s16.e1" /></sentence><sentence text=" Therefore, fluvoxamine may facilitate the anxiolytic effect of tandospirone via CYP3A4 inhibition"><entity charOffset="12-23" id="DDI-PubMed.18950380.s17.e0" text="fluvoxamine" /><entity charOffset="64-76" id="DDI-PubMed.18950380.s17.e1" text="tandospirone" /><pair ddi="false" e1="DDI-PubMed.18950380.s17.e0" e2="DDI-PubMed.18950380.s17.e0" /><pair ddi="false" e1="DDI-PubMed.18950380.s17.e0" e2="DDI-PubMed.18950380.s17.e1" /></sentence><sentence text="" /></document>